Drug Approval | January 14, 2022
WHO recommends two new drugs for COVID-19
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
It is the first monoclonal antibody drug for use in any animal species
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The last date to apply for this program is 18th January 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
